Table 4.

Relative risks and 95% confidence intervals for sitting time and site-specific cancer incidence in men, 1992–2009

Leisure-time spent sitting (h/d)
Cancer site<33–56 or more
Total cancerDeaths/person-years7,762/366,8146,792/308,7312,959/128,206
Age-adj. Ratea2,1972,2872,314
MV-adj. RRb (95% CI)1.00 (ref)0.99 (0.96–1.03)1.00 (0.96–1.05)
MV-adj. RRc (95% CI)1.00 (ref)0.99 (0.96–1.03)1.00 (0.96–1.05)
Head and neckDeaths/person-years109/366,814107/308,73158/128,206
Age-adj. Ratea303645
MV-adj. RRb (95% CI)1.001.04 (0.79–1.36)1.22 (0.88–1.69)
MV-adj. RRc (95% CI)1.001.04 (0.79–1.37)1.22 (0.88–1.69)
EsophagusDeaths/person-years119/366,814102/308,73149/128,206
Age-adj. Ratea343438
MV-adj. RRb (95% CI)1.000.97 (0.74–1.27)1.05 (0.75–1.48)
MV-adj. RRc (95% CI)1.000.96 (0.73–1.26)1.04 (0.74–1.46)
StomachDeaths/person-years89/366,814101/308,73136/128,206
Age-adj. Ratea263628
MV-adj. RRb (95% CI)1.001.23 (0.92–1.65)1.04 (0.70–1.55)
MV-adj. RRc (95% CI)1.001.23 (0.92–1.65)1.05 (0.71–1.55)
Colon and rectumdDeaths/person-years646/366,814553/308,731248/128/206
Age-adj. Ratea182186194
MV-adj. RRb (95% CI)1.000.96 (0.85–1.07)1.03 (0.89–1.19)
MV-adj. RRc (95% CI)1.000.95 (0.84–1.07)1.01 (0.87–1.18)
LiverDeaths/person-years82/366,81459/308,73130/128,206
Age-adj. Ratea242123
MV-adj. RRb (95% CI)1.000.76 (0.54–1.07)0.84 (0.55–1.29)
MV-adj. RRc (95% CI)1.000.75 (0.53–1.06)0.83 (0.54–1.28)
GallbladderDeaths/person-years12/366,81612/308,7319/128,206
Age-adj. Ratea347
MV-adj. RRb (95% CI)1.001.21 (0.54–2.74)2.14 (0.89–5.16)
MV-adj. RRc (95% CI)1.001.19 (0.53–2.69)2.11 (0.87–5.09)
PancreasdDeaths/person-years178/366,814165/308,73182/128,206
Age-adj. Ratea525966
MV-adj. RRb (95% CI)1.001.07 (0.86–1.33)1.17 (0.89–1.53)
MV-adj. RRc (95% CI)1.001.06 (0.85–1.31)1.14 (0.87–1.49)
LungDeaths/person-years775/366,814772/308,731356/128,206
Age-adj. Ratea224260279
MV-adj. RRb (95% CI)1.001.02 (0.92–1.13)1.01 (0.89–1.15)
MV-adj. RRc (95% CI)1.001.03 (0.93–1.14)1.01 (0.89–1.15)
MelanomaDeaths/person-years494/366,814466/308,731194/128,206
Age-adj. Ratea139158153
MV-adj. RRb (95% CI)1.001.10 (0.96–1.25)1.05 (0.89–1.24)
MV-adj. RRc (95% CI)1.001.10 (0.96–1.25)1.05 (0.88–1.24)
KidneyDeaths/person-years141/366,814179/308,73159/128,206
Age-adj. Ratea406147
MV-adj. RRb (95% CI)1.001.49 (1.19–1.86)1.11 (0.82–1.52)
MV-adj. RRc (95% CI)1.001.47 (1.17–1.84)1.09 (0.80–1.48)
BladderDeaths/person-years541/366,814435/308,731211/128,206
Age-adj. Ratea160150168
MV-adj. RRb (95% CI)1.000.94 (0.83–1.08)1.01 (0.86–1.19)
MV-adj. RRc (95% CI)1.000.94 (0.83–1.07)1.01 (0.86–1.19)
Non-Hodgkin lymphomaDeaths/person-years415/366,814389/308,731157/128,206
Age-adj. Ratea118135125
MV-adj. RRb (95% CI)1.001.13 (0.98–1.30)1.05 (0.87–1.26)
MV-adj. RRc (95% CI)1.001.12 (0.97–1.29)1.04 (0.86–1.25)
Multiple myelomaDeaths/person-years104/366,814101/308,73138/128,206
Age-adj. Ratea303432
MV-adj. RRb (95% CI)1.001.15 (0.87–1.52)1.02 (0.70–1.48)
MV-adj. RRc (95% CI)1.001.14 (0.86–1.50)1.00 (0.68–1.45)
ProstateeDeaths/person-years3,782/366,8143,157/308,7311,337/128,206
Age-adj. Ratea1,0541,0381,029
MV-adj. RRb (95% CI)1.000.94 (0.90–0.99)0.96 (0.90–1.02)
MV-adj. RRc (95% CI)1.000.94 (0.90–0.99)0.97 (0.91–1.03)
Advanced prostateeDeaths/person-years785/366,814652/308,731268/128,206
Age-adj. Ratea218215210
MV-adj. RRb (95% CI)1.000.95 (0.86–1.04)0.96 (0.85–1.09)
MV-adj. RRc (95% CI)1.000.95 (0.86–1.04)0.96 (0.85–1.09)
All other sites combinedDeaths/person-years640/366,814576/308,731254/128,106
Age-adj. Ratea183199202
MV-adj. RRb (95% CI)1.001.03 (0.92–1.15)1.03 (0.89–1.20)
MV-adj. RRc (95% CI)1.001.03 (0.92–1.15)1.03 (0.89–1.19)
  • aRate per 100,000 standardized to the age-adjusted distribution of the CPS-II population.

  • bAdjusted for physical activity (exercise, daily-life, and light housekeeping), race, smoking status, duration and frequency of smoking among current smokers, years since quitting among former smokers, education, alcohol consumption, total energy intake, red/processed meat intake, family history of cancer, prevalent chronic disease, and diabetes.

  • cAdditional adjustment for BMI.

  • dAlso adjusted for endoscopy screening.

  • eAlso adjusted for PSA testing.